Jason Wiles

Company: Avilar Therapeutics

Job title: Vice President, Discovery and Preclinical Sciences

Seminars:

Heterobifunctional Molecules That Induce Targeted Degradation of Extracellular Proteins Through the Cell-Surface Asialoglycoprotein Receptor 11:00 am

Clinically validating targeted intracellular protein degradation using the ubiquitin-proteasome system (UPS) motivated us to expand degradation approaches to extracellular proteins using a non-UPS pathway Harnessing the natural ASGPR pathway to access the endolysosome of hepatocytes for protein degradation. Heterobifunctional molecules (ASGPR-Targeting Chimeras or ATACs) recruit target proteins of interest through their extracellular domain while interacting…Read more

day: Post-Conference Focus Day: Next Generation TPD